Coherus BioSciences Management to Present at 36th NASDAQ OMX Investor Program
June 01 2017 - 9:00AM
Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that
senior management will present at the 36th NASDAQ OMX Investor
Program on Thursday, June 15, 2017 in London, UK at 11:30 am
GMT.
The audio portion of the presentations will be
available on the investors page of the Coherus BioSciences website
at http://investors.coherus.com.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global
biosimilar company that develops and commercializes high-quality
therapeutics for major regulated markets. Biosimilars are intended
for use in place of existing, branded biologics to treat a range of
chronic and often life-threatening diseases, with the potential to
reduce costs and expand patient access. Composed of a team of
proven industry veterans with world-class expertise in process
science, analytical characterization, protein production, sales
& marketing and clinical-regulatory development, Coherus is
positioned as a leader in the global biosimilar marketplace.
Coherus is advancing three late-stage clinical products towards
commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214
(etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as
well as developing a robust pipeline of future products in four
therapeutic areas, oncology, immunology (anti-TNF), ophthalmology
and multiple sclerosis. For additional information, please visit
www.coherus.com.
CONTACT:
Patrick O'Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
pobrien@coherus.com
+1 (650) 649-3527
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Sep 2023 to Sep 2024